Mizuho reiterates BridgeBio stock rating on patent settlement news By Investing.com

BridgeBio Pharma got a positive litigation update as Hikma and Pfizer settled in case 1:23-cv-00879, removing a key overhang and reinforcing Mizuho’s Outperform rating and $106 price target. Mizuho said the settlement likely falls in the 2033-2035 timeframe and could support BridgeBio trading in the $90-$110 range near term versus the current $72.25 share price. The article also cites other bullish analyst coverage, including Piper Sandler’s $111 target and H.C. Wainwright’s $100 target.

Analysis

The immediate winner is BBIO, but the more important read-through is that the market is steadily de-risking the durability of the revenue base behind the ATTR-CM franchise. Every incremental settlement likely reduces the probability of an adverse launch-date surprise and extends the period in which the incumbent can price rationally, which matters more to NPV than any single case outcome. The key second-order effect is on volatility: as legal variance compresses, the stock should migrate from event-driven trading toward fundamentals-driven rerating, which tends to attract a different shareholder base and support multiple expansion.

The bigger strategic implication is that the legal cloud may be clearing at the same time the company is trying to convert awareness into diagnosis. That creates a powerful operating leverage setup: if awareness campaigns lift screening rates even modestly, prescription growth can accelerate faster than consensus expects because ATTR-CM is underdiagnosed, not ignored. In that scenario, the patent news is not just a litigation relief event; it becomes a catalyst for institutional investors to re-underwrite BBIO as a franchise asset with a longer commercial runway.

For PFE, the settlement is a mild negative only insofar as it likely narrows the set of pathways to a more favorable competitive outcome, but the larger point is that market participants may be overpricing optionality around litigation. If the structured settlement indeed points to later entry, the economic damage is pushed far enough out that it becomes a 2030s issue rather than a near-term earnings issue. That means the stock reaction, if any, should be limited unless the market starts extrapolating broader IP weakness across the rare-disease platform.

The contrarian risk is that investors may be overestimating how much of the legal overhang was actually embedded already; if so, BBIO could stall in the near term even with better headlines. The cleaner setup is not chasing the spike, but using any post-event fade to build a position into the next commercial data or regulatory catalyst. A key reversal trigger would be any hint that competitive launches or pricing concessions arrive sooner than the current legal structure implies.

Key Decisions for Investors

• Long BBIO on a 2-6 week horizon into any post-settlement consolidation; target a move toward the high-$80s/low-$90s if the market starts repricing lower legal risk, with a stop below the pre-event range if sentiment fails to hold.
• Sell put spreads in BBIO rather than buying stock outright; use 1-3 month maturities to monetize elevated implied volatility while defining downside if the market has already fully priced the headline.
• Pair trade: long BBIO / short a basket of higher-duration biotech names with weaker near-term catalysts over the next 1-2 months; the thesis is BBIO-specific de-risking while broader biotech remains rates-sensitive.
• Maintain a tactical underweight in PFE rather than an outright short; the settlement is not an earnings event, but it reduces upside convexity from litigation optionality over the next 6-12 months.
• Use any BBIO rally toward the analyst range as a trimming zone unless upcoming commercial adoption data confirms that awareness is translating into prescriptions; the trade becomes much better if commercial acceleration shows up within one quarter.